Charles Schwab Investment Management Inc. cut its position in Teleflex Incorporated (NYSE:TFX - Free Report) by 16.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 338,850 shares of the medical technology company's stock after selling 68,353 shares during the period. Charles Schwab Investment Management Inc. owned 0.73% of Teleflex worth $46,826,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also recently made changes to their positions in TFX. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Teleflex by 103.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company's stock worth $27,000 after acquiring an additional 100 shares during the last quarter. Banque Cantonale Vaudoise acquired a new stake in shares of Teleflex in the first quarter worth approximately $27,000. Costello Asset Management INC acquired a new stake in shares of Teleflex in the first quarter worth approximately $28,000. Whipplewood Advisors LLC boosted its stake in shares of Teleflex by 7,700.0% in the first quarter. Whipplewood Advisors LLC now owns 234 shares of the medical technology company's stock worth $32,000 after acquiring an additional 231 shares during the last quarter. Finally, Allworth Financial LP boosted its stake in shares of Teleflex by 504.8% in the first quarter. Allworth Financial LP now owns 254 shares of the medical technology company's stock worth $34,000 after acquiring an additional 212 shares during the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. Truist Financial lowered their price target on Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a research note on Monday, May 5th. Wall Street Zen raised Teleflex from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 2nd. Mizuho upped their target price on Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a report on Friday, August 1st. Royal Bank Of Canada raised their target price on Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a research note on Friday, August 1st. Finally, Morgan Stanley cut their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating for the company in a research note on Monday, May 5th. One research analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $141.57.
Read Our Latest Research Report on TFX
Insider Transactions at Teleflex
In related news, Director Gretchen R. Haggerty acquired 500 shares of Teleflex stock in a transaction that occurred on Wednesday, August 6th. The shares were purchased at an average cost of $114.75 per share, for a total transaction of $57,375.00. Following the acquisition, the director owned 6,305 shares in the company, valued at approximately $723,498.75. This represents a 8.61% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jaewon Ryu acquired 1,500 shares of Teleflex stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average price of $115.00 per share, for a total transaction of $172,500.00. Following the completion of the acquisition, the director owned 3,727 shares in the company, valued at $428,605. This trade represents a 67.36% increase in their position. The disclosure for this purchase can be found here. Insiders bought 5,500 shares of company stock worth $633,590 in the last 90 days. Insiders own 1.40% of the company's stock.
Teleflex Trading Up 1.3%
Shares of TFX traded up $1.5750 during midday trading on Wednesday, reaching $125.8750. The company had a trading volume of 269,706 shares, compared to its average volume of 791,667. Teleflex Incorporated has a 1-year low of $108.90 and a 1-year high of $249.90. The stock has a market cap of $5.56 billion, a PE ratio of 29.62, a price-to-earnings-growth ratio of 1.67 and a beta of 1.08. The firm has a 50 day simple moving average of $117.85 and a 200-day simple moving average of $131.65. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42.
Teleflex (NYSE:TFX - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.36 by $0.37. The business had revenue of $780.90 million during the quarter, compared to the consensus estimate of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The company's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the company earned $3.42 EPS. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Research analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.
Teleflex Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 15th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, August 15th. Teleflex's payout ratio is 32.00%.
About Teleflex
(
Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Featured Stories

Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.